Asarina Pharma

About Us

Asarina Pharma Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Our product pipeline is built on over 40 years of research, and with our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions from Tourette syndrome to OCD..

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Asarina Pharma AB (publ) Year-end 2019 Report released

Fri, Feb 21, 2020 08:00 CET

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a directed share issue.”FINANCIAL HIGHLIGHTS · Total operating expenses amounted to SEK 20.8 million, of which about 2/3 were clinical costs related to the Phase II studies in PMDD and menstrual migraine. · The company conducted a directed share issue in October 2019,

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Asarina Pharma AB (publ) Year-end 2019 Report released

Subscribe